POLQ inhibition also enhances PARP inhibitor effectiveness and activates the cGAS-STING pathway in an HRD pancreatic adenocarcinoma mouse model, suggesting that it may have applications in ICB immunotherapy, in which STING agonists are also under investigation [253]. Here, STING1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.